Ethical considerations in the relationship between physicians and the pharmaceutical industry

Psychiatric Clinics of North America

Volumn 25, Issue 3, 2002, Pages 647-663

  Wazana, Ashley ^a,b,d   Primeau, François ^c  

^a Centre Hospitalier De Soins Psychiatriques De l'Abitibi Témiscamingue   (Canada)

^b Columbia University ^*  (United States)

^c ST MARY S HOSPITAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; DRUG INDUSTRY; DRUG MARKETING; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL ETHICS; MEDICAL PRACTICE; PHARMACEUTICS; PRIORITY JOURNAL; PSYCHIATRY; REVIEW;

EID: 0036731804     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0193-953x(01)00016-8     Document Type: Review

References (73)

1. Doctors, drug companies, and gifts
2. Teaching drug promotion abuses to health profession students
3. Attitudes of general practitioners in New Zealand to pharmaceutical representatives
4. Understanding financial conflict of interest
5. Beyond conflict of interest
6. Fever pitch: Getting doctors to prescribe is big business
7. Drug companies still trying to buy our doctors' endorsements
8. Patients perceptions of physician acceptance of gifts from the pharmaceutical industry
9. A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts
10. Recipe for danger: An interview with Shawn Collins
11. Scientific versus commercial sources of influence on the prescribing behaviour of physicians
12. The impact of drug company funding on the content of continuing medical education
13. The accuracy of drug information from pharmaceutical representatives
14. Physicians attitudes towards pharmaceutical sales representatives
15. The effect of resident attitudes of regulatory policies regarding pharmaceutical representative activities
16. Physicians, pharmaceutical sales representatives and the cost of prescribing
17. Interactions with the pharmaceutical industry: Experiences and attitudes of psychiatry residents, interns and clerks
18. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior
19. The effect of educational gifts from pharmaceutical firms on medical students' recall of company names or products
20. Family physicians and generic drugs: A study of recognition, information sources, prescribing attitudes and practices
21. Changes in drug prescribing patterns related to commercial company funding of continuing medical education
22. Physicians' behavior and their interaction with drug companies: A controlled study of physicians who requested additions to a hospital drug formulary
23. Rational prescribing and sources of information
24. Pharmaceutical representatives in academic medical centres: Interaction with faculty and staff
25. The effects of pharmaceutical firm enticements on physician prescribing behaviour: There's no such thing as free lunch
26. The role of commercial sources in the adoption of a new drug
27. When pharmaceutical manufacturer's employees present grand rounds, what do residents remember?
28. Is a gift ever just a gift: A critical review of the interaction between physicians and the pharmaceutical industry
29. La tentation pharmaceutique
30. Attitudes of medical school faculty toward gifts from the pharmaceutical industry
31. Policies regulating the activities of pharmaceutical representatives in residency programs
32. Involvement of pharmacy faculty in the development of policies for pharmaceutical sales representatives
33. Complimentary journeys to the World Congress of Gastroenterology: An inquiry of potential sponsors and beneficiaries
34. Encounters with pharmaceutical sales representatives among practising internists
35. Beliefs and practices of emergency medicine faculty and residents regarding interactions with the biomedical industry
36. Impact of pharmaceutical company representatives on internal medicine residency programs
37. Pharmaceutical policies in Canadian family medicine training: Survey of residency programs
38. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives
39. Pharmaceutical representatives and emergency medicine residents: A national survey
40. Interactions with the pharmaceutical industry: A survey of family medicine residents in Ontario
41. Pharmaceutical branding of residents
42. Of principles and pens: Attitudes and practices of medicine housestaff toward pharmaceutical industry promotions
43. National survey of the attitudes of Canadian physicians towards drug-detailing by pharmaceutical representatives
44. Content analysis of drug-detailing by pharmaceutical representatives
45. The science of persuasion
46. Primary care physicians believe that CA blockers and ACE inhibitors are superior to B-blockers and diuretics in treating uncomplicated hypertension
47. Secular changes in published clinical trials of second-line agents in rheumatoid arthritis
48. Influences on the quality of published drug studies
49. The quality of drug studies published in symposium proceedings
50. Source of funding and outcome of clinical trials
51. Funding clinical research
52. Is research into the treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected?
53. Publication of sponsored symposiums in medical journals
54. Meta-analysis of tacrine for Alzheimer disease: The influence of industry sponsors
55. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis
56. Conflict of interest in the debate over calcium-channel antagonist
57. Beyond conflict of interest. Sponsored drug trials show more-favourable outcomes
58. The environment and disease: Association or causation
59. On the nature of evidence
60. Initiating, conducting and maintaining guidelines development programs
61. CMA policy summary. Physicians and the pharmaceutical industry (update 1993)
62. Guidelines for corporate participation in annual meetings
63. Physicians and the pharmaceutical industry
64. Gifts to physicians from industry
65. Canadian Psychiatric Association guidelines in relating to the pharmaceutical industry
66. Conflict of Interest in Research. Guidelines for faculty involvement in commercially supported continuing medical education
67. Residents and the pharmaceutical industry: How to preserve ethical integrity
68. Examining the physician-detailer interaction
69. The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice
70. Effects of an educational intervention on residents' knowledge and attitudes towards interactions with pharmaceutical representatives